October 2024
Relay Therapeutics Announces Additional Layoffs to Achieve $50M Annual Savings
Relay Therapeutics, layoffs, cost-cutting, biotech industry, workforce reduction
Recordati Acquires Sanofi’s Rare Disease Drug Enjaymo in $825M Deal
Recordati, Sanofi, Enjaymo, rare disease, cold agglutinin disease (CAD), pharmaceutical acquisition
BIOSECURE Act: Navigating Industry Implications and Future Directions
BIOSECURE Act, Biotechnology industry, Supply chain disruptions, Chinese pharmaceutical imports, U.S. manufacturing capabilities, Contract development and manufacturing organizations (CDMOs), Pharmaceutical supply chain resilience
FDA Approves BMS’ Opdivo for Perioperative Treatment of Resectable Non-Small Cell Lung Cancer
Opdivo (nivolumab), Perioperative treatment, Resectable non-small cell lung cancer (NSCLC), FDA approval, CheckMate-77T trial, Neoadjuvant and adjuvant therapy
Relay Therapeutics Announces 10% Workforce Reduction to Streamline Research Organization
Relay Therapeutics, layoffs, workforce reduction, biotech, research organization, streamlining
Gene Therapy Pioneer Jim Wilson Launches Franklin Biolabs, Expanding Genetic Medicine Services
Jim Wilson, Franklin Biolabs, Gene Therapy, Genetic Medicine Services, Rare Diseases, Adeno-Associated Viruses (AAVs)
FDA Declares End to Tirzepatide Shortage, Impacting Compounded Versions of Mounjaro and Zepbound
tirzepatide shortage, FDA, Mounjaro, Zepbound, compounded medications, GLP-1 drugs
Flagship’s Winning Streak Continues with Singapore R&D Partnership
Flagship, R&D collaboration, Singapore, biotech, innovation
Johnson & Johnson Abandons 340B Rebate Plan Following HRSA Pressure and Congressional Advocacy
340B drug discount program, Johnson & Johnson, HRSA, rebate model, healthcare policy, pharmaceutical pricing
BioMarin and CAMP4 Collaborate on RNA-Targeting Therapies for Rare Genetic Diseases
BioMarin, CAMP4, RNA-targeting therapies, genetic diseases, regulatory RNA, RAP Platform, antisense oligonucleotides, ASOs, rare genetic conditions